NOTICE: The Drug Law Center is no longer accepting these type of cases. This page is strictly for informational purposes. We appreciate your cooperation and understanding by not contacting our office on these cases. We are actively investigating and prosecuting cases involving Valsartan cancers. For information on Valsartan lawsuits, look here.
Postoperative deep vein thrombosis (DVT) can be a significant problem after a Stryker hip revision surgery, leading to lethal complications. Many times, DVT is challenging to diagnose because classic clinical symptoms and signs are not always present. If the doctor is not suspicious or curious of obvious lacking signs, the individual can develop significantly serious problems, which could lead to death.
In 2009, the Stryker orthopedic medical device company began marketing its Rejuvenate and ABG II modular hip replacement systems. Originally, the hip implants were thought to be far superior to traditional metal-on-metal hip replacement devices. Unfortunately, by July 2012, Stryker voluntarily recalled their hip replacement systems due to significant issues including injury and death related to DVT and other medical problems.